The global research report prenatal testing and newborn screening market has been substantially affected by the pandemic, and changes can be seen in the market dynamics and demand trends. In April 2019, Progenity Inc. introduced the Resura Prenatal Test, which is a non-invasive and personalized prenatal check for monogenetic diseases. Such newer tests are ensuring safety of infants, which is estimated to drive market growth in the coming future. The chromosomal anomalies include benefits by genetic material, which can differ from chromosome to chromosome, and thus, have applications in prenatal testing. There is a rise in the adoption of advanced prenatal testing and newborn screening for detecting genetic problems among kids and newborn babies.
The global study prenatal testing and newborn screening health emergency has beleaguered the global economy, thereby disrupting this particular business domain’s functioning mechanism. This prenatal testing and newborn screening growth is attributable to its growing adoption due to the ability of ultrasound diagnosis for detection of anomalies in the position of the baby coupled with actions within the womb. The study offers an in-depth analysis of the product outlook, which depicts the latest production growth trends and profit valuation. It further fragments the global prenatal testing and newborn screening market into a broad product spectrum. Additionally, testing, such as the Trisomy 21 test, is considered superior than other modalities screenings.
To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/prenatal-testing-an...
The study elaborates on the crucial information pertaining to the regional market share. It simultaneously focuses on the significant details about the growth patterns of each regional market. The report closely studies the growth trajectory of the global prenatal testing and newborn screening market. It brings to light the global dominance of the leading regional segments, including North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.
Regional Outlook (Revenue, USD Billion; 2017-2027)
North America
• U.S.
• Canada
• Mexico
Europe
• Germany
• U.K.
• France
• BENELUX
• Rest of Europe
Type Outlook (Revenue, USD Billion; 2017-2027)
• Prenatal Testing
• Newborn Screening